Literature DB >> 19235042

Differential effects of selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations.

Nur Ozten Kandaş1, Carla Randolph, Maarten C Bosland.   

Abstract

We examined the hypothesis that nontoxic concentrations of selenium induce apoptosis and growth inhibition selectively in prostate cancer cells but not in benign prostate cells. Nontumorigenic BPH-1 prostate epithelial cells, androgen-sensitive LNCaP, and androgen-independent PC-3 prostate cancer cells were exposed to sodium selenite at 1 to 10 micromol/l for 24 to 72 h. Cell proliferation, viability, and apoptosis were assessed by MTT assay, trypan blue exclusion, flow cytometry, DNA laddering, and caspase activation. BPH-1 cells were more sensitive for cytotoxic selenium effects than malignant prostate cells, whereas LNCaP cells were more sensitive than PC-3 cells. At noncytotoxic selenium concentrations, there was no apoptosis in BPH-1 and PC-3 cells and no growth inhibition of LNCaP and BPH-1 cells. PC-3 cells were refractory to apoptosis induction but were growth inhibited at noncytotoxic concentrations. LNCaP cells were growth stimulated at 1 micromol/l and sensitive to apoptosis induction at higher noncytotoxic concentrations. Thus, noncytotoxic selenite concentrations did not induce growth inhibition or apoptosis selectively in prostate cancer cells. Growth stimulation of LNCaP cells by low concentrations suggests the possibility of adverse effects of selenium supplementation on hormone sensitive prostate cancer, whereas inhibition of PC-3 cell proliferation at noncytotoxic concentrations suggests potential benefit of selenium in advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19235042      PMCID: PMC2821820          DOI: 10.1080/01635580802398430

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  53 in total

1.  The interferon-beta and tamoxifen combination induces apoptosis using thioredoxin reductase.

Authors:  D J Lindner; E R Hofmann; S Karra; D V Kalvakolanu
Journal:  Biochim Biophys Acta       Date:  2000-04-17

2.  In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention.

Authors:  C Ip; H J Thompson; Z Zhu; H E Ganther
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

Review 3.  Molecular targets for selenium in cancer prevention.

Authors:  Y S Kim; J Milner
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

Review 4.  Mechanisms of organoselenium compounds in chemoprevention: effects on transcription factor-DNA binding.

Authors:  B W Youn; E S Fiala; O S Sohn
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

Review 5.  Antiangiogenic activity of selenium in cancer chemoprevention: metabolite-specific effects.

Authors:  J Lu; C Jiang
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

Review 6.  Molecular mechanisms of cancer prevention by selenium compounds.

Authors:  J Fleming; A Ghose; P R Harrison
Journal:  Nutr Cancer       Date:  2001       Impact factor: 2.900

7.  Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase.

Authors:  Linda Björkhem-Bergman; Kerstin Jönsson; Lennart C Eriksson; Jerker M Olsson; Sören Lehmann; Christer Paul; Mikael Björnstedt
Journal:  Biochem Pharmacol       Date:  2002-05-15       Impact factor: 5.858

8.  Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line.

Authors:  W Zhong; T D Oberley
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

9.  Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial.

Authors:  Anna J Duffield-Lillico; Mary E Reid; Bruce W Turnbull; Gerald F Combs; Elizabeth H Slate; Lori A Fischbach; James R Marshall; Larry C Clark
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-07       Impact factor: 4.254

10.  Supplementation of healthy volunteers with nutritionally relevant amounts of selenium increases the expression of lymphocyte protein biosynthesis genes.

Authors:  Vasileios Pagmantidis; Catherine Méplan; Evert M van Schothorst; Jaap Keijer; John E Hesketh
Journal:  Am J Clin Nutr       Date:  2008-01       Impact factor: 7.045

View more
  19 in total

Review 1.  Selenium for preventing cancer.

Authors:  Marco Vinceti; Gabriele Dennert; Catherine M Crespi; Marcel Zwahlen; Maree Brinkman; Maurice P A Zeegers; Markus Horneber; Roberto D'Amico; Cinzia Del Giovane
Journal:  Cochrane Database Syst Rev       Date:  2014-03-30

Review 2.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

Review 3.  Selenium for preventing cancer.

Authors:  Gabriele Dennert; Marcel Zwahlen; Maree Brinkman; Marco Vinceti; Maurice P A Zeegers; Markus Horneber
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

4.  Selenium supplementation and prostate cancer mortality.

Authors:  Stacey A Kenfield; Erin L Van Blarigan; Natalie DuPre; Meir J Stampfer; Edward L Giovannucci; June M Chan
Journal:  J Natl Cancer Inst       Date:  2014-12-12       Impact factor: 13.506

5.  L-selenomethionine does not protect against testosterone plus 17β-estradiol-induced oxidative stress and preneoplastic lesions in the prostate of NBL rats.

Authors:  Nur Özten; Michael Schlicht; Alan M Diamond; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2014-04-28       Impact factor: 2.900

Review 6.  Environmental Selenium and Human Health: an Update.

Authors:  Marco Vinceti; Tommaso Filippini; Lauren A Wise
Journal:  Curr Environ Health Rep       Date:  2018-12

7.  Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure.

Authors:  Gustav Nilsonne; Eric Olm; Adam Szulkin; Filip Mundt; Agnes Stein; Branka Kocic; Anna-Klara Rundlöf; Aristi P Fernandes; Mikael Björnstedt; Katalin Dobra
Journal:  J Exp Clin Cancer Res       Date:  2009-06-29

8.  A Perspective on Prostate Carcinogenesis and Chemoprevention.

Authors:  Maarten C Bosland; Nur Ozten; Jillian N Eskra; Abeer M Mahmoud
Journal:  Curr Pharmacol Rep       Date:  2015-04-11

9.  Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence.

Authors:  Nur Ozten-Kandaş; Maarten C Bosland
Journal:  J Carcinog       Date:  2011-11-30

10.  Carmustine enhances the anticancer activity of selenite in androgen-independent prostate cancer cells.

Authors:  Vijayalakshmi Thamilselvan; Mani Menon; Sivagnanam Thamilselvan
Journal:  Cancer Manag Res       Date:  2012-11-09       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.